Advertisement

Current Management of Ocular Surface Squamous Neoplasia (OSSN)

  • S. Madison Duff
  • Niloofar Piri
  • Hossein AsghariEmail author
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

Ocular surface squamous neoplasia (OSSN) is a superficial conjunctival and cornea tumor but 3–9% can have intraocular invasion and approximately 1–6% can have orbital invasion. Primary treatment remains surgical but use of topical chemotherapy has greatly improved the outcome for extensive lesions and for recurrent tumors. Radiation and enucleation or exenteration are reserved for extensive lesions.

Keywords

Squamous cell carcinoma Carcinoma in situ (CIN) Mitomycin Interferon 5-Fluorouracil 

References

  1. 1.
    Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol. 1995;39:429–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Basti S, Macsai MS. Ocular surface squamous neoplasia: a review. Cornea. 2003;22:687–704.PubMedCrossRefGoogle Scholar
  3. 3.
    Tananuvat N, Lertprasertsuke N. Ocular surface squamous neoplasia. In: Srivastava S. Intraepithelial neoplasia; 2012. ISBN: 978–953–307-987-5. InTech. http://www.intechopen.com/books/intraepithelial-neoplasia/ocular-surface-squamous-neoplasia. Accessed 20 Jul 2017.
  4. 4.
    Sepulveda R, Pe’er J, Midena E, et al. Topical chemotherapy for ocular surface squamous neoplasia: current status. Br J Ophthalmol. 2010;94:532–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Frucht-Pery J, Rozenman Y. Mitomycin C therapy for corneal intraepithelial neoplasia. Am J Ophthalmol. 1994;117(2):164–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anti-Cancer Drugs. 1990;1:5e13.CrossRefGoogle Scholar
  7. 7.
    Shields CL, Demirci H, Marr BP, et al. Chemoreduction with topical mitomycin C prior to resection of extensive squamous cell carcinoma of the conjunctiva. Arch Ophthalmol. 2005;123:109–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Gupta A, Muecke J. Treatment of ocular surface squamous neoplasia with mitomycin C. Br J Ophthalmol. 2010;94:555–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Besley J, Pappalardo J, Lee GA, et al. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b. Am J Ophthalmol. 2014;157(2):287–93.PubMedCrossRefGoogle Scholar
  10. 10.
    Rozenman Y, Frucht-Pery J. Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C. Cornea. 2000;19:1–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Prabhasawat P, Tarinvorakup P, Tesavibul N, et al. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea. 2005;24:443–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol. 2010;94(10):1316–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Ramasubramanian A, Shields CL, Sinha N, Shields JA. Ocular surface squamous neoplasia after corneal graft. Am J Ophthalmol. 2010;149(1):62–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Wilson MW, Hungerford JL, George SM, et al. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol. 1997;124:303–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Frucht-Pery J, Rozenman Y, Pe’er J. Topical mitomycin-C for partially excised conjunctival squamous cell carcinoma. Ophthalmology. 2002;109:548–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Shields CL, Naseripour M, Shields JA, et al. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol. 2002;133:601–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen C, Louis D, Dodd T, et al. Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol. 2004;88:17–8.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Birkholz ES, Goins KM, Sutphin JE, Kitzmann AS, Wagoner MD. Treatment of ocular surface squamous cell intraepithelial neoplasia with and without mitomycin C. Cornea. 2011;30(1):37–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Rudkin AK, Dempster L, Muecke JS. Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy. Clin Exp Ophthalmol. 2015;43(1):20–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Özcan AA, Çiloğlu E, Esen E, Şimdivar GH. Use of topical bevacizumab for conjunctival intraepithelial neoplasia. Cornea. 2014;33:1205–9.PubMedCrossRefGoogle Scholar
  21. 21.
    McKelvie PA, Daniell M. Impression cytology following mitomycin C therapy for ocular surface squamous neoplasia. Br J Ophthalmol. 2001;85:1115–9.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    de Keizer RJW, de Wolff-Rouendall D, van Delft JL. Topical application of 5-fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid. Doc Ophthalmol. 1986;64:31–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Yeatts RP, Engelbrecht NE, Curry CD, et al. 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology. 2000;107:2190–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Yeatts RP, Ford JG, Stanton CA, et al. Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctival and cornea. Ophthalmology. 1995;102:1338–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Midena E, Degli Angeli C, Valenti M, de Belvis V, Boccato P. Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol. 2000;84:268–72.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Rudkin AK, Muecke JS. Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol. 2011;95:947–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Parrozzani R, Frizziero L, Trainiti S, et al. Topical 1% 5-fluorouracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study. Br J Ophthalmol. 2017;101:1094–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Parrozzani R, Lazzarini D, Alemany-Rubio E, et al. Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study. Br J Ophthalmol. 2011;95:355–9.  https://doi.org/10.1136/bjo.2010.183244.PubMedCrossRefGoogle Scholar
  29. 29.
    Joag MG, Sise A, Murillo JC, et al. Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology. 2016;123(7):1442–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Maskin SL. Regression of limbal epithelial dysplasia with topical interferon. Arch Ophthalmol. 1994;112:1145–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol. 1995;155(4):2240–7.PubMedGoogle Scholar
  32. 32.
    Karp CL, Galor A, Chhabra S, Barnes SD, Alfonso EC. Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology. 2010;117(12):2241–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Vann RR, Karp CL. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. Ophthalmology. 1999;106:91–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Karp CL, Moore JK, Rosa RH. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology. 2001;108:1093–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Boehm MD, Huang AJ. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology. 2004;111:1755–61.PubMedCrossRefGoogle Scholar
  36. 36.
    Galor A, Karp CL, Chhabra S, et al. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol. 2010;94:551–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Schechter BA, Koreishi AF, Karp CL, Feuer W. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b. Ophthalmology. 2008;115:1291–l6.PubMedCrossRefGoogle Scholar
  38. 38.
    Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol. 2013;24:336–42.PubMedCrossRefGoogle Scholar
  39. 39.
    Faramarzi A, Feizi S. Subconjunctival bevacizumab injection for ocular surface squamous neoplasia. Cornea. 2013;32:998–1001.PubMedCrossRefGoogle Scholar
  40. 40.
    Paul S, Stone DU. Intralesional bevacizumab use for invasive ocular surface squamous neoplasia. J Ocul Pharmacol Ther. 2012;28:647–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Asena L, Dursun Altinors D. Topical Nevacizumab for the treatment of ocular surface squamous neoplasia. J Ocul Pharmacol Ther. 2015;31(8):487–90.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Finger PT, Chin KJ. Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study. Ophthal Plast Reconstr Surg. 2012;28:85–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Adler E, Turner JR, Stone DU. Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012. Cornea. 2013;32:1558–61.PubMedCrossRefGoogle Scholar
  44. 44.
    Arepalli S, Kaliki S, Shields CL, et al. Plaque radiotherapy in the management of scleral-invasive conjunctival squamous cell carcinoma: an analysis of 15 eyes. JAMA Ophthalmol. 2014;132:691–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Shields JA, Shields CL, DePotter P. Surgical management of conjunctival tumors. Arch Ophthalmol. 1997;115:808–15.PubMedCrossRefGoogle Scholar
  46. 46.
    Sudesh S, Rapuano CJ, Cohen EJ, Eagle RC Jr, Laibson PR. Surgical management of ocular surface squamous neoplasms: the experience from a cornea center. Cornea. 2000;19(3):278–83.PubMedCrossRefGoogle Scholar
  47. 47.
    Palamar M, Kaya E, Egrilmez S, Akalin T, Yagci A. Amniotic membrane transplantation in surgical management of ocular surface squamous neoplasias: long-term results. Eye. 2014;28(9):1131–5.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Cha SB, Shields CL, Shields JA, Eagel RC Jr, De Potter P, Talansky M. Massive precorneal extension of squamous cell carcinoma of the conjunctiva. Cornea. 1993;12(6):537–40.PubMedCrossRefGoogle Scholar
  49. 49.
    Pizzarello LD, Jacobiec FA. Bowen’s disease of the conjunctiva: a misnomer. In: Jacobiec FA, editor. Ocular and adnexal tumors. Birmingham, AL: Aesculapius; 1978. p. 553–71.Google Scholar
  50. 50.
    Erie JC, Campbell RJ, Liesegang TJ. Conjunctival and corneal intraepithelial and invasive neoplasia. Ophthalmology. 1986;93:176–83.PubMedCrossRefGoogle Scholar
  51. 51.
    Li AS, et al. Recurrence of ocular surface squamous neoplasia treated with excisional biopsy and cryotherapy. Am J Ophthalmol. 2015;160(2):213–219.e1.PubMedCrossRefGoogle Scholar
  52. 52.
    Siedlecki AN, Tapp S, Tosteson ANA, et al. Surgical versus interferon alpha-2b treatment strategies for ocular surface squamous neoplasia: a literature-based decision analysis. Cornea. 2016;35(5):613–8.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Tabin G, Levin S, Snibson G, et al. Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. Ophthalmology. 1997;104:485–92.PubMedCrossRefGoogle Scholar
  54. 54.
    Philipp W, Daxecker F, Langmayr J, Gottinger W. Spontaneous corneal rupture after strontium irradiation of a conjunctival squamous cell carcinoma. Ophthalmologica. 1987;195:113–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Lommatzsch P. Beta-ray treatment of malignant epithelial tumors of the conjunctiva. Am J Ophthalmol. 1976;81:198–206.PubMedCrossRefGoogle Scholar
  56. 56.
    Kearsley JH, Fitchew RS, Taylor RG. Adjunctive radiotherapy with strontium-90 in the treatment of conjunctival squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 1988;14(3):435–43.PubMedCrossRefGoogle Scholar
  57. 57.
    Lui H, Hobbs L, Tope WD, Lee PK, Elmets C, Provost N, Chan A, Neyndorff H, Su XY, Jain H, Hamzavi I, McLean D, Bissonnette R. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol. 2004;140(1):26–32.PubMedCrossRefGoogle Scholar
  58. 58.
    Barbazetto IA, Lee TC, Abramson DH. Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. Am J Ophthalmol. 2004;138(2):183–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • S. Madison Duff
    • 1
  • Niloofar Piri
    • 1
  • Hossein Asghari
    • 1
    Email author
  1. 1.University of Louisville OphthalmologyLouisvilleUSA

Personalised recommendations